Coronavirus | ICMR says no payment made for Chinese test kits supplies
The HinduIndia does not stand to lose a single rupee, said the Indian Council of Medical Research on Monday in response to a clarification sought on the alleged profiteering by distributors, exposed through a legal dispute between an importer and a distributor, in the delivery COVID-19 rapid antibody testing kits to it. The matter came to light when Rare Metabolics Life Sciences Pvt Ltd and Aark Pharmaceuticals, distributors of Chinese Wondfo Biotech’s kits imported by Matrix Labs, approached the High Court recently to get delivery/payment disputes cleared. Advisory to States ICMR noted that the States have been advised to stop using the kits procured from Wondfo and Zhuhai Livzon Diagnostics after it found wide variation in their sensitivity despite early promise of good performance for surveillance purpose. “Several States have procured rapid antibody test kits and on their demand, ICMR has also provided these kits with clear instructions that they are to be used only for surveillance purpose. ICMR, thereafter, evaluated the kits in field conditions and the results have shown wide variation in their sensitivity despite early promise of good performance for surveillance purposes.